Consequently, the World Health Organization (WHO) and other public health bodies have now associated obesity with an elevated risk for at least 13 different types of cancer, including colorectal, postmenopausal breast, pancreatic, and endometrial cancers
In 2025, the company reported a +4.31% YoY revenue growth, driven by its specialty segment momentum: Austedo ($2.21B) continues to be the key growth driver with strong uptake in movement disorders, Copaxone ($255M) continues its decline due to generic competition, while UZEDY ($191M) is gaining early traction as a long-acting injectable for schizophrenia, reflecting Tevas push into differentiated CNS therapies
They work through several important mechanisms: They increase insulin release from the pancreas when blood glucose is high They reduce excess glucose release from the liver They slow stomach emptying, helping prevent sharp glucose spikes after meals They increase feelings of fullness, often reducing appetite Because these effects depend on blood glucose levels, GLP-1 medications on their own carry a very low risk of causing low blood sugar (hypoglycaemia)
None of these compounded products have been studied either short or long term for safety, efficacy, or weight regain after stopping them
However, switching between medications depends on several factors, like current response, side effects, dosage, and overall health
There may be some evidence, though questionable, that active ingredients like berberine and green tea might curb cravings and reduce appetite a bit , but the effects are not dramatic enough for this to be an FDA-approved strategy. In other words, the patches are likely much ado about nothing
